Management of the myeloproliferative disorders : distinguishing data from dogma

Hematol J. 2004:5 Suppl 3:S126-32. doi: 10.1038/sj.thj.6200438.
No abstract available

Publication types

  • Review

MeSH terms

  • Abnormalities, Drug-Induced / etiology
  • Abnormalities, Drug-Induced / prevention & control
  • Adult
  • Aged
  • Anticoagulants / therapeutic use
  • Contraindications
  • Female
  • Humans
  • Hydroxyurea / therapeutic use
  • Interferon-alpha / therapeutic use
  • Male
  • Middle Aged
  • Myeloproliferative Disorders / diagnosis
  • Myeloproliferative Disorders / therapy*
  • Phlebotomy
  • Polycythemia Vera / diagnosis
  • Polycythemia Vera / mortality
  • Polycythemia Vera / therapy
  • Pregnancy
  • Pregnancy Complications, Hematologic / drug therapy
  • Prognosis
  • Quinazolines / therapeutic use
  • Randomized Controlled Trials as Topic
  • Thrombocythemia, Essential / complications
  • Thrombocythemia, Essential / diagnosis
  • Thrombocythemia, Essential / drug therapy
  • Thrombophilia / drug therapy
  • Thrombophilia / etiology

Substances

  • Anticoagulants
  • Interferon-alpha
  • Quinazolines
  • anagrelide
  • Hydroxyurea